Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi's Lixisenatide Shows Challenges Of Being Late Entrant In Class

Executive Summary

Safety and efficacy of what would be sixth GLP-1 agonist seem solid, but FDA advisory committee notes concerns about allergic reactions, dosing and relative effectiveness.

Advertisement

Related Content

Keeping Track: FDA Approves Adlyxin, Accepts Brineura, Lowers Hurdle For Xadago
Sanofi's Adlyxin Merely Another Option For Type 2 Diabetes Treatments
Keeping Track: FDA Nixes Medicure’s Aggrastat For STEMI, Approves Insys’ Syndros
Sanofi's Lixisenatide Gets Clean Bill Of Health On CV Safety, Heart Failure
FDA CV Requirements Sideline Sanofi’s Lixisenatide

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057666

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel